dcTRAILR1 Inhibitors
dcTRAILR1 inhibitors encompass a range of chemicals targeting crucial signaling pathways associated with apoptosis and cell survival. Curcumin, a natural polyphenol, inhibits NF-κB signaling by stabilizing IκBα, indirectly promoting apoptosis in cancer cells by modulating dcTRAILR1-associated processes related to cell survival and death. Sorafenib, a multi-kinase inhibitor, disrupts Raf/MEK/ERK signaling pathways, indirectly influencing dcTRAILR1 by altering MAPK signaling and impacting processes related to apoptosis and cell survival. Bortezomib, a proteasome inhibitor, stabilizes IκBα, disrupting NF-κB-driven anti-apoptotic signals and promoting apoptosis in cancer cells through its influence on dcTRAILR1-associated processes. LY294002, a PI3K inhibitor, disrupts the PI3K-Akt-mTOR pathway, indirectly affecting dcTRAILR1 by altering downstream events and influencing processes related to apoptosis and cell survival. Thalidomide, an immunomodulatory drug, promotes IκBα stabilization, disrupting NF-κB-driven anti-apoptotic signals and impacting dcTRAILR1-associated processes.
SB203580, a p38 MAPK inhibitor, disrupts p38 MAPK signaling, indirectly influencing dcTRAILR1 by altering downstream events and impacting processes related to apoptosis and cell survival. Dasatinib, a dual BCR-ABL and Src family kinase inhibitor, modulates tyrosine kinase signaling, indirectly affecting dcTRAILR1-associated processes. Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway, indirectly influencing dcTRAILR1 by altering downstream events and impacting processes related to apoptosis and cell survival. Cisplatin, a DNA cross-linking agent, induces DNA damage and activates JNK signaling, indirectly modulating dcTRAILR1-associated processes. Trametinib, a MEK1/2 inhibitor, disrupts the MAPK pathway, indirectly affecting dcTRAILR1 by altering downstream events and influencing processes related to apoptosis and cell survival. Obatoclax, a Bcl-2 family inhibitor, disrupts mitochondrial membrane potential, promoting intrinsic apoptosis and impacting dcTRAILR1-associated processes. Imatinib, a tyrosine kinase inhibitor, targets Bcr-Abl and c-Kit signaling pathways, indirectly affecting dcTRAILR1 by altering downstream events and influencing processes related to apoptosis and cell survival. This diverse set of inhibitors provides valuable tools for dissecting the intricate regulatory networks associated with dcTRAILR1 and its role in cellular processes pivotal for various pathological conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin, a natural polyphenol, inhibits NF-κB signaling by suppressing IκBα degradation. Its action indirectly modulates dcTRAILR1 by preventing NF-κB-driven anti-apoptotic signals, promoting apoptosis in cancer cells. This influences dcTRAILR1-associated processes related to cell survival and death. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, targets Raf/MEK/ERK signaling pathways. Its impact on the MAPK pathway indirectly influences dcTRAILR1 by altering downstream signaling, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, prevents NF-κB activation by stabilizing IκBα. Its action indirectly modulates dcTRAILR1 by disrupting NF-κB-driven anti-apoptotic signals, promoting apoptosis in cancer cells. This influences dcTRAILR1-associated processes related to cell survival and death. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, disrupts the PI3K-Akt-mTOR pathway. Its influence on PI3K-mediated signaling indirectly affects dcTRAILR1 by altering downstream events, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide, an immunomodulatory drug, inhibits NF-κB activation by promoting IκBα stabilization. Its action indirectly modulates dcTRAILR1 by disrupting NF-κB-driven anti-apoptotic signals, promoting apoptosis in cancer cells. This influences dcTRAILR1-associated processes related to cell survival and death. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, disrupts the p38 MAPK signaling pathway. Its impact on p38 MAPK-mediated signaling indirectly influences dcTRAILR1 by altering downstream events, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a dual BCR-ABL and Src family kinase inhibitor, modulates tyrosine kinase signaling. Its impact on Src family kinases indirectly influences dcTRAILR1 by altering downstream events, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway. Its influence on mTOR-mediated signaling indirectly affects dcTRAILR1 by altering downstream events, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin, a DNA cross-linking agent, induces DNA damage and activates JNK signaling. Its action indirectly modulates dcTRAILR1 by altering JNK-mediated signaling, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a MEK1/2 inhibitor, disrupts the MAPK pathway. Its impact on MEK-mediated signaling indirectly influences dcTRAILR1 by altering downstream events, impacting dcTRAILR1-associated processes related to apoptosis and cell survival. | ||||||